Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

Christoph KrispRobert ParkerDana PascoviciNicholas K HaywardJames S WilmottJohn F ThompsonGraham J MannGeorgina V LongRichard A ScolyerMark P Molloy

Published in: British journal of cancer (2018)

These results demonstrate the utility of proteomic phenotyping to identify both putative biomarkers of response to MEK inhibition and prognostication associated with metastatic melanoma.

Keyphrases

high throughput
pi k akt
label free
signaling pathway
cell proliferation
dna methylation